C8-02: Study of Incidences, Time Trends of Female Lung Cancer, Survivals and Its Predictive Factors on Shanghai Population
Liao Meilin,Chen Zhiwei,Zheng Yin
DOI: https://doi.org/10.1097/01.jto.0000283237.83959.23
IF: 20.121
2007-01-01
Journal of Thoracic Oncology
Abstract:In order to further characterize the difference of gender on the clinical, pathological status, survival and its predictive factors of patients on population-based lung cancer, and to determine time trends of gender differences, we analyzed the data which had been entered into Shanghai Cancer Registry System and executed by CDC. Data on demographics, stage at diagnosis, history and survival were obtained for all patients with primary bronchogenic carcinoma registered in Shanghai cancer registry system from 2002 to 2004. The time trends of the male and female incidence in the urban population from 1972 to 2004 were assessed using APC (annual percent change) analysis. Relative survival rates based on life-table analysis methods were calculated to estimate the benefit of cancer survival by compensating for the expected difference in baseline survival rates between male and female populations. Cox multi-variance analyses were used to evaluate prognostic factors; those factors were gender, age, residential area, pathological type, stage, and hospital grade. 23196 new cases of lung cancer were diagnosed during 2002 – 2004, the female crude incidence rate was 33.73/100000, and age-adjusted rate was 30.90/100000. The male crude incidence rate and the age-adjusted rate were higher than those of female. The APC of male and female crude incidence continued to rise during the past 33 years (1.723% vs 2.036%, p ≤0.01). The male age-adjusted incidence rate in tendency to reduce was seen in the urban area (APC was -0.605%, p ≤0.01), but no change in female (APC was -0.136, p >0.05). There were more stage IV cases and adenocarcinoma in women than those of men (47.5% vs. 40.0%, 86.1% vs. 47.8%, respectively, p ≤0.05).The overall 3-year survival rates and MST were significantly higher in women than men (17.05% vs. 14.01% 0.83 year vs. 0.77 year, p ≤ 0.01). Stage-specific survival rates of women were also statistically higher than those of men for each stage (p ≤ 0.05). The 3-year survival rates and MST were also significantly higher in women adenocarcinoma than men (30.38%: 22.66%, 1.48 year: 0.98 year, p ≤0.01). Female gender was an independent positive prognostic factor (p ≤ 0.01) by a multivariate Cox analysis, other positive prognostic factors were younger, urban area, squamous cancer, early stage, high-grade hospital. Shanghai is one of the high-incidence area of lung cancer in the world. The present study confirms that women had statistically better outcomes than men in different stages of disease. The reasons behind these gender differences remain unclear. Exogenous or endogenous estrogens, gene, smoking, psychology, etc, may play roles to develop of the lung cancer in women.